Previous Article |
Table of Contents
| Next Article
* X-Ceptor Therapeutics, 4757 Nexus Center Drive, San Diego, CA
92121; Edited by Jan L. Breslow, The Rockefeller University, New York,
NY, and approved July 1, 2002 (received for review April 4, 2002)
Recent studies have identified the liver X receptors (LXR The contribution of elevated
cholesterol levels to cardiovascular disease necessitates tight control
over cholesterol synthesis and transport. Indeed, classical studies
have described the negative feedback loop by which elevations in
intracellular cholesterol repress transcription of genes involved in
cholesterol synthesis (1). In contrast, recent studies suggest the
existence of a positively acting cholesterol-responsive pathway
regulated by the liver X receptors (LXRs). LXR Analysis of LXR function using genetic knockouts and synthetic agonists
has identified important roles for this family of transcription factors
in the control of cholesterol and lipid metabolism including regulating
the genes encoding ATP binding cassette (ABC) transporters involved in
sterol absorption and cholesterol transport (3-6). In addition, LXRs
directly or indirectly regulate a number of genes involved in
cholesterol and fatty acid metabolism including the gene encoding the
sterol regulatory binding element protein 1c, a master
transcriptional regulator of fatty acid synthesis (5, 7).
Although originally described as regulators of entero-hepatic function
(8), the identification of LXRs as direct regulators of ABC transporter
gene expression in peripheral cells such as macrophages suggests a
broad role for these receptors in whole-body cholesterol homeostasis
(9). In particular, LXR directly regulates expression of ABCA1 and
apolipoprotein E (ApoE) in nonhepatic tissues (4, 5, 10). Both ABCA1
and ApoE have important functions in cellular cholesterol efflux
mechanisms that promote transfer of excess intracellular cholesterol to
extracellular acceptors such as high density lipoprotein (HDL)
particles, a process termed reverse cholesterol transport (9). The
importance of reverse cholesterol transport is highlighted by Tangier
disease, a rare genetic form of HDL deficiency caused by mutations in
the gene encoding ABCA1. Tangier disease patients exhibit reductions in
HDL levels, accumulate cholesterol in peripheral tissues, and have an
increased risk for atherosclerosis (11-13).
Both LXR Animals.
Homozygous ApoE Isolation of Mouse Peritoneal and Bone Marrow-Derived Macrophages.
Thioglycolate-elicited peritoneal macrophages were isolated from mice 4 days after peritoneal injection of thioglycolate broth media.
Macrophages were stained with oil red O by rinsing adherent cells with
50% isopropanol for 1 min and then with 0.5% oil red O for 5 min. To
isolate bone marrow-derived macrophages, femurs and tibias from
LXR RNA Isolation and Analysis of Gene Expression by Quantitative
Reverse Transcription-PCR.
Real-time PCR was performed by using a Perkin-Elmer/ABI 7700 Prism.
Probes and primers were designed by using Primer Express (Applied
Biosystems). Levels of cyclophilin were measured in all samples, and
the results are presented as number of target transcripts per
cyclophilin transcript.
Bone Marrow Transplantation.
Recipient ApoE Lipid and Lipoprotein Analyses.
Free and esterified cholesterol, plasma cholesterol, and triglyceride
levels were determined by enzymatic assays by using the supplier's
protocols (Sigma).
Analysis of Atherosclerosis.
The extent of atherosclerosis in en face mouse aortas was
quantitated by computer-assisted image analysis (16, 17).
Immunohistochemical analysis of aortic root sections was performed by
using procedures as described (17).
Statistical Analyses.
Results were analyzed by one-way ANOVA and/or Student's unpaired
t test by using GraphPad (San Diego)
PRISM.
LXRs Are Antiatherogenic Factors in Vivo.
To investigate the role of LXR activity in macrophages, peritoneal
macrophages isolated from LXR
Medical Sciences
Identification of macrophage liver X receptors as inhibitors
of atherosclerosis
,
,
,
,
,¶, and
Howard Hughes Medical Institute, Department of
Pathology and Laboratory Medicine, and § Department of
Medicine, University of California, Los Angeles, CA 90095; and
Howard Hughes Medical Institute, Department of
Pharmacology, University of Texas Southwestern Medical Center, Dallas,
TX 75390-9050
![]()
Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
and
LXR
) as important regulators of cholesterol metabolism and transport. LXRs control transcription of genes critical to a range of
biological functions including regulation of high density
lipoprotein cholesterol metabolism, hepatic cholesterol
catabolism, and intestinal sterol absorption. Although LXR activity has
been proposed to be critical for physiologic lipid metabolism and
transport, direct evidence linking LXR signaling pathways to the
pathogenesis of cardiovascular disease has yet to be established. In
this study bone marrow transplantations were used to selectively
eliminate macrophage LXR expression in the context of murine models of
atherosclerosis. Our results demonstrate that LXRs are
endogenous inhibitors of atherogenesis. Additionally,
elimination of LXR activity in bone marrow-derived cells mimics many
aspects of Tangier disease, a human high density lipoprotein
deficiency, including aberrant regulation of cholesterol transporter
expression, lipid accumulation in macrophages, splenomegaly, and
increased atherosclerosis. These results identify LXRs as targets for
intervention in cardiovascular disease.
![]()
Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
(NR1H3) and LXR
(NR1H2) are members of the nuclear hormone receptor superfamily of
transcription factors and are bound and activated by naturally
occurring oxidized forms of cholesterol (2).
and LXR
are expressed in macrophages, a cell type
that is required for the formation of atherosclerotic lesions and is
particularly sensitive to perturbations in cholesterol homeostasis
(14). To directly address the role of LXR activity in atherogenesis, we
used bone marrow transplantation to create macrophage-selective
knockouts in the context of established mouse models of atherosclerosis
(15). These studies identify LXRs as antiatherogenic factors in
vivo and directly link LXR activity to the pathogenesis of atherosclerosis.
![]()
Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
/
mice, low density
lipoprotein receptor mice (LDLR
/
), and
C57BL/6 mice were from The Jackson Laboratory. Homozygous LXR

/
and
LXR
+/+ mice in a mixed genetic background
(C57BL/6 × 129Sv) were from a breeding colony established and
maintained at X-Ceptor Therapeutics. Both the
LXR

/
and
LXR
+/+ mice have been backcrossed to each
other since their original creation in 1999.

+/+ and
LXR

/
mice were flushed with DMEM
containing 10% FBS. After lysis of red blood cells, bone marrow cells
were cultured in DMEM containing 30% L929 cell conditioned media and
10% lipid-depleted serum. RNA was isolated after 24 h of
ligand treatment.
/
and
LDLR
/
mice (10 weeks of age) were lethally
irradiated with 900 rads (9 Gy) and transplanted with bone marrow cells
(3 × 106) from 6- to 8-week-old donor mice
via tail vein injection. For transplantations into
ApoE
/
mice two independent bone marrow
transplantations were carried out. Male donors with female recipients
were used for the 8-week experiment (n = 7 for
LXR
+/+
ApoE
/
and LXR

/
ApoE
/
groups, n = 6 for
ApoE
/
ApoE
/
).
In contrast, female donors with male recipients were used for the
16-week experiment (n = 6 for
LXR
+/+
ApoE
/
group, n = 10 for the
LXR

/
ApoE
/
group, and n = 7 for
the ApoE
/
ApoE
/
group. Similarly, two independent transplantations into
LDLR
/
mice were evaluated. Male donors with
female recipients were used for the 6-week experiment
(n = 11 for LXR
+/+
LDLR
/
, n = 12 for
LXR

/
LDLR
/
, and n = 6 for
LDLR
/
LDLR
/
).
In the 20-week experiment female donors with male recipients were used
(n = 5 for LXR
+/+
LDLR
/
and n = 8 for the
LXR

/
LDLR
/
).
![]()
Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

+/+ and
LXR

/
mice were cultured in
vitro. Microscopic examination revealed a striking accumulation of
oil red O-positive droplets in LXR

/
macrophages, indicative of lipid accumulation (Fig.
1a). Little or no oil red O
staining is observed in LXR
+/+ macrophages
(Fig. 1b). Quantitative analysis of cholesterol levels indicates that LXR

/
macrophages
contained a 2.7-fold increase in free cholesterol and a 2.4-fold
increase in total cholesterol compared with
LXR
+/+ (Fig. 1c). No difference
in triglyceride content is observed between
LXR
+/+ and
LXR

/
macrophages. The elevated
cholesterol levels observed in LXR

/
macrophages are consistent with reports demonstrating that LXR regulates genes involved in cholesterol transport including ABCA1 and
ApoE (5-7, 10).

View larger version (60K):
[in a new window]
Fig. 1.
Cholesterol accumulation in LXR 

/
macrophages. Oil
red O-stained peritoneal macrophages from LXR

/
(a) and LXR
+/+ (b)
mice. (c) Total and free cellular cholesterol content of
LXR
+/+ (empty bars) and LXR

/
(filled bars) macrophages. * indicates significantly different
from LXR
+/+ controls (total cholesterol
P < 0.002, free cholesterol P = 0.05).
To specifically examine the role of LXR in macrophages, we first used
bone marrow-derived macrophages to further define the role of LXRs in
the regulation of macrophage gene expression. As shown in Fig.
2, treatment of
LXR
+/+ macrophages with the LXR pan-agonist
T0901317 (7) produces a 3- to 5-fold induction of the mRNAs encoding
ABCA1, ABCG1 (a second ABC transporter implicated in cholesterol
transport) (18), and ApoE. This ligand-dependent induction is enhanced
when an agonist for LXR's heterodimeric partner the retinoid X
receptor (RXR) (LG268) (19) is also included. Importantly, the response of all three genes to LXR and RXR agonists is completely eliminated in
LXR

/
macrophages (Fig. 2).
|
Because LXRs are active in bone marrow-derived macrophages, we
generated a selective knockout of LXR activity in an atherogenic genetic background by transplanting bone marrow cells from
LXR

/
mice into lethally irradiated ApoE
knockout mice (ApoE
/
).
ApoE
/
mice develop spontaneous hyperlipidemia
and extensive atherosclerosis, and these mice are widely used to
evaluate the impact of therapeutic agents on atherogenesis (15).
Importantly, studies have shown that reconstitution of recipient
ApoE
/
mice with ApoE+/+
bone marrow results in normalization of plasma cholesterol levels and
protection from atherosclerosis caused by expression of ApoE in donor
macrophages (15). Thus in this experimental paradigm only cells derived
from bone marrow precursors, including macrophages, are
LXR
/
. In contrast, LXRs are present in the
liver and intestine where they are known to be crucial for proper
cholesterol and fatty acid metabolism (9).
Evaluation of plasma lipid levels in recipient mice biweekly after
transplantation indicated that, as expected because of macrophage ApoE
expression, plasma cholesterol levels in
LXR
+/+
ApoE
/
mice decline by week two and are reduced by 40% 16 weeks after transplantation (Fig. 3a and
Table 1, which is published as supporting information on the
PNAS web site, www.pnas.org). This result is consistent with published
reports demonstrating that reconstitution with
ApoE+/+ macrophages provides sufficient
macrophage-derived ApoE to promote clearance of plasma apolipoprotein
B-containing lipoproteins (15). Interestingly, plasma cholesterol
levels in LXR

/
ApoE
/
mice are significantly higher than the
levels observed in LXR
+/+
ApoE
/
mice (Fig.
3a and Table 1).
Previous work has demonstrated that the ApoE gene is itself a
target for LXR regulation in macrophages (10) and immunohistochemical
analysis (Fig. 3 b-d) indicates that ApoE is
expressed at lower levels in aortic root lesions from
LXR

/
ApoE
/
mice when compared with
LXR
+/+
ApoE
/
lesions 16 weeks after transplantation. The decrease in ApoE staining
suggests that the inability of LXR

/
bone marrow to normalize cholesterol levels in the
ApoE
/
mice may be caused, at least in part,
by aberrant regulation of macrophage ApoE expression.
|
To evaluate the role of LXR in atherosclerotic lesion development,
atherosclerosis was quantified by en face analysis of aortas (16) from recipient mice at 8 weeks and at 14 weeks after bone marrow
transplantation (Fig. 4). Interestingly,
aortas from LXR

/
ApoE
/
mice exhibit 3- to 8-fold more
atherosclerotic lesions throughout the entire aorta compared with
LXR
+/+
ApoE
/
mice. As expected from previous studies (15), a substantial reduction
of atherosclerosis is observed when LXR
+/+
ApoE
/
mice are compared with
ApoE
/
ApoE
/
controls (2- to 4-fold). The results of the en face analysis were confirmed by quantitation of oil red O-stained aortic root sections 8 weeks after transplantation (see Fig. 7, which is
published as supporting information on the PNAS web site).
Immunohistochemical staining of aortic root sections with antibodies to
the macrophage-specific marker Moma-2 demonstrated that the cellular
composition of the lesions is not significantly different in the three
transplant genotypes (see Fig. 8, which is published as
supporting information on the PNAS web site).
|
Antiatherogenic Activity in LDLR
/
Mice.
To further explore the antiatherogenic activity of LXRs we turned to a
second animal model of atherosclerosis, the
LDLR
/
mouse. The
LDLR
/
model differs from the
ApoE
/
model in several respects that are
particularly relevant to the analysis of macrophage LXR activity.
First, in contrast to ApoE, there is no evidence that the LDLR gene is
directly regulated by LXR. Second, transplantation of
LDLR+/+ bone marrow into
LDLR
/
recipients does not lower cholesterol
levels or reduce the severity of atherosclerosis (15), allowing
LXR
+/+ and
LXR

/
macrophages to be compared under
conditions of equivalent cholesterol loads. Third, significant
atherosclerosis is observed only in LDLR
/
mice fed a high-fat diet (15). This requirement for both genetic and
environmental risk factors to induce atherosclerosis in
LDLR
/
mice is thought to better reflect the
interplay between genetic and lifestyle contributions in human
cardiovascular disease.
To investigate the contribution of macrophage LXRs to atherosclerosis
in LDLR
/
mice,
LDLR
/
recipients were irradiated and
reconstituted with LXR
+/+-,
LXR

/
-, and
LDLR
/
-derived bone marrow. One week after
transplantation mice were placed on a Western diet (21% fat, 0.15%
cholesterol) and maintained for an additional 5 weeks. As expected, the
Western diet induced a significant time-dependent increase in serum
cholesterol levels in all three groups of mice (Fig.
5a). In contrast to the
ApoE
/
study, however, there were no
differences in cholesterol levels among the three experimental groups
(Fig. 5a), nor were there differences in lipoprotein
profiles analyzed by FPLC (see Table 2, which is published as
supporting information on the PNAS web site). Importantly, in this
study all of the donors and recipients have normal hepatic expression
of ApoE, which accounts for more than 90% of circulating ApoE levels
(15). Thus differences in macrophage ApoE expression among the
LXR
+/+
LDLR
/
,
LXR

/
LDLR
/
, and LDLR
/
LDLR
/
groups should not influence serum
cholesterol levels as they would in the ApoE
/
system. Although all of the animals in the study experienced a similar
cholesterol burden, reconstitution with
LXR

/
bone marrow
(LXR

/
LDLR
/
) resulted in a significant increase in
atherosclerosis compared with either LXR
+/+
LDLR
/
(3.2-fold) or
LDLR
/
LDLR
/
mice (2.3-fold) (Fig. 5b and Fig. 9, which is published as
supporting information on the PNAS web site).
|
To further evaluate the long-term effects of macrophage LXR deficiency
in vivo, the LDLR
/
transplant
described above was repeated with recipient mice maintained on a
Western diet for 19 weeks. Quantitation of atherosclerosis once again
demonstrated a 3-fold increase in lesion area when LXR

/
LDLR
/
mice are compared with
LXR
+/+
LDLR
/
animals (see Fig. 10, which is published as supporting
information on the PNAS web site). Furthermore, morphological
examination of mice at necropsy revealed that the spleens of
LXR

/
LDLR
/
mice are dramatically enlarged (Fig.
6a; average spleen weight for
LXR

/
LDLR
/
mice = 154 mg, average spleen
weight for LXR
+/+
LDLR
/
= 80 mg). Histologic analysis of frozen
sections shows increased oil red O staining in spleens from
LXR

/
LDLR
/
indicating excess lipid accumulation
(Fig. 6 b and c). Splenomegaly was not observed
in the 8-week experiment, suggesting that a prolonged exposure to high
serum cholesterol levels is required to manifest this phenotype. The
observation of splenomegaly resulting, at least in part, from lipid
accumulation is reminiscent of Tangier disease patients who present
with splenomegaly caused by the accumulation of lipid-rich macrophages
(20). In conclusion, the results presented here identify LXRs as
endogenous inhibitors of atherosclerosis and key
determinants of macrophage lipid accumulation and foam cell formation.
|
| |
Discussion |
|---|
|
|
|---|
The observation that LXRs mediate the sterol-dependent induction of reverse cholesterol transport in macrophages via direct regulation of target genes such as ABCA1 and ApoE (9) prompted an examination of the role of these receptors in atherosclerotic lesion development. To examine the relationship between LXR and atherosclerosis, bone marrow transplantations were used to selectively eliminate LXR activity in bone marrow-derived cells. This selective knockout allowed us to investigate the contribution of macrophage LXR activity to atherogenesis without complications arising from the loss of LXR functions in other tissues. Selective loss of bone marrow LXR activity increases atherosclerotic lesion development in two different mouse models, suggesting that these receptors function as endogenous inhibitors of atherogenesis. Thus, these observations provide a direct link between LXR activity and cardiovascular disease. Furthermore, the ability to regulate LXR activity by the direct binding of synthetic small molecules suggests that LXR ligands may prove useful in the treatment of atherosclerosis.
The increased atherosclerosis generated by transfer of LXR-deficient
bone marrow into ApoE
/
and
LDLR
/
mice highlights macrophages and fatty
atherosclerotic lesions themselves as direct sites of action for
potential LXR-based therapeutic agents. In support of this conclusion
we and others have shown that LXRs regulate gene expression and
cholesterol transport in macrophages cultured in vitro (6,
21). In contrast to the antiatherogenic activities of LXRs in
macrophages, treatment of experimental animals with LXR agonists
elevates serum triglycerides, most likely resulting from induction of
sterol regulatory binding element protein 1c and other genes involved
in fatty acid synthesis in the liver (7). Because hypertriglyceridemia
can be a contributing factor for cardiovascular disease, tissue or cell
type-specific LXR ligands will most likely be needed to maximize the
therapeutic potential of LXR-based drugs. Thus, the identification of
macrophages as critical targets for LXR action should facilitate the
development of effective LXR-based therapies. Although macrophage
function is absolutely required for atherosclerotic lesion development (14), the possibility that the absence of LXR activity in other bone
marrow-derived cell types contributes to the observed phenotypes cannot
yet be excluded.
The ability of LXRs to regulate expression of genes encoding proteins
that participate in reverse cholesterol transport including ABCA1 and
ApoE provides a straightforward explanation for the increase in
atherosclerosis observed with LXR

/
macrophages. One would predict that elimination of LXR activity would
at least partially mimic an ABCA1 deficiency. Consistent with this
hypothesis, we and others have shown that
LXR

/
macrophages accumulate cholesterol
and exhibit defects in ABCA1 gene expression and reverse cholesterol
transport (6, 21). Similarly Aiello et al. (22) have shown
that ABCA1-deficient macrophages increase atherosclerosis when
transplanted into ApoE
/
mice. The dramatic
splenomegaly observed when LXR

/
bone
marrow is introduced in LDLR
/
mice also
supports a role for LXRs in cholesterol transport. Accumulation of
lipid-enriched cells in the spleen, as we observed in
LXR

/
LDLR
/
mice, is associated with Tangier
disease and other forms of lipid storage diseases (20). Nevertheless,
we cannot rule out the possibility that LXR-dependent pathways distinct
from reverse cholesterol transport also impact atherosclerosis. For
instance a recent report has implicated LXR in the regulation tumor
necrosis factor
, an inflammatory cytokine (23). We have not,
however, observed consistent differences in cytokine levels when
macrophages from LXR+/+ and
LXR
/
are compared. Analysis of quadruple
LXR

/
/ABCA1
/
/ApoE
/
mice will be needed to determine the contribution of ABCA1 regulation to the antiatherogenic activity of LXR.
Recent studies have associated two other nuclear receptors, RXR and the
peroxisome proliferator-activated receptor
(PPAR
), with the
pathogenesis of atherosclerosis. Treatment of atherogenic mouse models
with RXR or PPAR
agonists decreases atherosclerotic lesions (21,
24), and both RXR and PPAR
can impinge on LXR-regulated pathways.
Like many other nuclear receptors, LXRs bind to DNA and activate
transcription as heterodimers with RXR. RXR-LXR heterodimers are known
to respond to agonists for both receptors, and not surprisingly RXR
agonists mimic many of the effects of LXR activators including induction of ABCA1 and reverse cholesterol transport in macrophages (5,
21). Similarly, activation of PPAR
leads to a direct increase in the
expression of LXR
via a PPAR
binding site in the LXR
promoter
(25, 26). Consistent with our results demonstrating the antiatherogenic
effects of LXR, transplantation of PPAR
/
bone marrow into LDLR
/
mice also increases
atherosclerosis (25). These observations suggest that LXR is downstream
of PPAR
with regard to the antiatherogenic effects of PPAR
ligands.
The identification of LXRs as antiatherogenic factors suggests that synthetic LXR ligands may further increase the receptors' antiatherogenic potential by stimulating reverse cholesterol transport, particularly in macrophages. Importantly, current drug treatment for cardiovascular disease and hypercholesterolemia generally use statins to decrease LDL cholesterol by enzymatic inhibition of 3-hydroxy-3-methylglutaryl CoA reductase in the liver. Thus the combination of statins with mechanistically distinct LXR-based drugs provides an exciting opportunity for synergy, particularly in patients who do not fully respond to mono-therapy with statins alone.
| |
Acknowledgements |
|---|
We thank William Boisvert for advice on bone marrow transplantations. Additionally, we acknowledge Mari Manchester and Peter Edwards for helpful discussions. P.T. is an Assistant Investigator and D.J.M. is an Investigator of the Howard Hughes Medical Institute.
| |
Abbreviations |
|---|
LXR, liver X receptor;
ABC, ATP binding cassette;
ApoE, apolipoprotein E;
LDLR, low density lipoprotein receptor;
RXR, retinoid
X receptor;
PPAR
, peroxisome proliferator-activated receptor
.
| |
Footnotes |
|---|
¶ To whom reprint requests may be addressed. E-mail: ptontonoz{at}mednet.ucla.edu or ischulman{at}x-ceptor.com.
This paper was submitted directly (Track II) to the PNAS office.
| |
References |
|---|
|
|
|---|
| 1. | Brown, M. S. & Goldstein, J. L. (1992) Cell 71, 187-188[CrossRef][ISI][Medline] . |
| 2. | Repa, J. J. & Mangelsdorf, D. J. (1999) Curr. Opin. Biotechnol. 10, 557-563[CrossRef][ISI][Medline] . |
| 3. |
Berge, K. E.
, Tian, H.
, Graf, G. A.
, Yu, L.
, Grishin, N. V.
, Schultz, J.
, Kwiterovich, P.
, Shan, B.
, Barnes, R.
& Hobbs, H. H.
(2000)
Science
290,
1771-1775 |
| 4. |
Costet, P.
, Luo, Y.
, Wang, N.
& Tall, A. R.
(2000)
J. Biol. Chem.
275,
28240-28245 |
| 5. |
Repa, J. J.
, Turley, S. D.
, Lobaccaro, J. A.
, Medina, J.
, Li, L.
, Lustig, K.
, Shan, B.
, Heyman, R. A.
, Dietschy, J. M.
& Mangelsdorf, D. J.
(2000)
Science
289,
1524-1529 |
| 6. |
Venkateswaran, A.
, Laffitte, B. A.
, Joseph, S. B.
, Mak, P. A.
, Wilpitz, D. C.
, Edwards, P. A.
& Tontonoz, P.
(2000)
Proc. Natl. Acad. Sci. USA
97,
12097-12102 |
| 7. |
Schultz, J. R.
, Tu, H.
, Luk, A.
, Repa, J. J.
, Medina, J. C.
, Li, L.
, Schwendner, S.
, Wang, S.
, Thoolen, M.
, Mangelsdorf, D. J.
,
et al.
(2000)
Genes Dev.
14,
2831-2838 |
| 8. | Peet, D. J. , Turley, S. D. , Ma, W. , Janowski, B. A. , Lobaccaro, J.-M. A. , Hammer, R. E. & Mangelsdorf, D. J. (1998) Cell 93, 693-704[CrossRef][ISI][Medline] . |
| 9. |
Edwards, P. A.
, Kast, H. R.
& Anisfeld, A. M.
(2002)
J. Lipid Res.
43,
2-12 |
| 10. |
Laffitte, B. A.
, Repa, J. J.
, Joseph, S. B.
, Wilpitz, D. C.
, Kast, H. R.
, Mangelsdorf, D. J.
& Tontonoz, P.
(2001)
Proc. Natl. Acad. Sci. USA
98,
507-512 |
| 11. | Bodzioch, M. , Orso, E. , Klucken, J. , Langmann, T. , Bottcher, A. , Diederich, W. , Drobnik, W. , Barlage, S. , Buchler, C. , Porsch-Ozcurumez, M. , et al. (1999) Nat. Genet. 22, 347-351[CrossRef][ISI][Medline] . |
| 12. | Brooks-Wilson, A. , Marcil, M. , Clee, S. M. , Zhang, L. H. , Roomp, K. , van Dam, M. , Yu, L. , Brewer, C. , Collins, J. A. , Molhuizen, H. O. , et al. (1999) Nat. Genet. 22, 336-345[CrossRef][ISI][Medline] . |
| 13. | Rust, S. , Rosier, M. , Funke, H. , Real, J. , Amoura, Z. , Piette, J.-C. , Deleuze, J.-F. , Brewer, H. B. , Duverger, N. , Denefle, P. & Assmann, G. (1999) Nat. Genet. 22, 352-355[CrossRef][ISI][Medline] . |
| 14. | Glass, C. K. & Witztum, J. L. (2001) Cell 104, 503-516[CrossRef][ISI][Medline] . |
| 15. | Linton, M. F. & Fazio, S. (1999) Curr. Opin. Lipidol. 10, 97-105[CrossRef][Medline] . |
| 16. | Tangirala, R. K. , Rubin, E. M. & Palinski, W. (1995) J. Lipid Res. 36, 2320-2328[Abstract]. |
| 17. | Tangirala, R. K. , Tsukamoto, K. , Chun, S. H. , Usher, D. , Pure, E. & Rader, D. J. (1999) Circulation 100, 1816-1822[ISI][Medline] . |
| 18. |
Klucken, J.
, Buchler, C.
, Orso, E.
, Kaminski, W. E.
, Porsch-Ozcurumez, M.
, Liebisch, G.
, Kapinsky, M.
, Diederich, W.
, Drobnik, W.
, Dean, M.
,
et al.
(2000)
Proc. Natl. Acad. Sci. USA
97,
817-822 |
| 19. | Boehm, M. F. , Zhang, L. , Zhi, L. , McClurg, M. R. , Berger, E. , Wagoner, M. , Mais, D. E. , Suto, C. M. , Davies, J. A. , Heyman, R. A. , et al. (1995) J. Med. Chem. 38, 3146-3155[CrossRef][ISI][Medline] . |
| 20. | Serfaty-Lacrosniere, C. , Civeira, F. , Lanzberg, A. , Isaia, P. , Berg, J. , Janus, E. D. , Smith, M. P., Jr. , Pritchard, P. H. , Frohlich, J. , Lees, R. S. , et al. (1994) Atherosclerosis 107, 85-98[CrossRef][ISI][Medline] . |
| 21. |
Claudel, T.
, Leibowitz, M. D.
, Fievet, C.
, Tailleux, A.
, Wagner, B.
, Repa, J. J.
, Torpier, G.
, Lobaccaro, J. M.
, Paterniti, J. R.
, Mangelsdorf, D. J.
,
et al.
(2001)
Proc. Natl. Acad. Sci. USA
98,
2610-2615 |
| 22. |
Aiello, R. J.
, Brees, D.
, Bourassa, P. A.
, Royer, L.
, Lindsey, S.
, Coskran, T.
, Haghpassand, M.
& Francone, O. L.
(2002)
Arterioscler. Thromb. Vasc. Biol.
22,
630-637 |
| 23. |
Landis, M. S.
, Patel, H. V.
& Capone, J. P.
(2002)
J. Biol. Chem.
277,
4713-4721 |
| 24. | Li, A. C. , Brown, K. K. , Silvestre, M. J. , Willson, T. M. , Palinski, W. & Glass, C. K. (2000) J. Clin. Invest. 106, 523-531[ISI][Medline] . |
| 25. | Chawla, A. , Boisvert, W. A. , Lee, C. H. , Laffitte, B. A. , Barak, Y. , Joseph, S. B. , Liao, D. , Nagy, L. , Edwards, P. A. , Curtiss, L. K. , et al. (2001) Mol. Cell 7, 161-171[CrossRef][ISI][Medline] . |
| 26. |
Tobin, K. A.
, Steineger, H. H.
, Alberti, S.
, Spydevold, O.
, Auwerx, J.
, Gustafsson, J. A.
& Nebb, H. I.
(2000)
Mol. Endocrinol.
14,
741-752 |
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
I. Zanotti, F. Poti, M. Pedrelli, E. Favari, E. Moleri, G. Franceschini, L. Calabresi, and F. Bernini The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential J. Lipid Res., May 1, 2008; 49(5): 954 - 960. [Abstract] [Full Text] [PDF] |
||||